The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 4, 1997, Pages 628-633

  Lee, L Veronica ^a   Ewald, Gregory A ^a   McKenzie, Clark R ^a   Eisenberg, Paul R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cross linked fibrin degradation products; fibrinopeptide A; myocardial infarction; soluble fibrin

Indexed keywords

FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOPEPTIDE A; PROCOAGULANT;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIBRINOLYSIS; HEART DEATH; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; THROMBUS; TREATMENT OUTCOME;

EID: 0030963427     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.4.628     Document Type: Article

References (16)

1. Fletcher AP, Alkjaersig NK, Ghani FM, Tulevski V, Owens O. Blood coagulation system pathophysiology in acute myocardial infarction: the influence of anticoagulant treatment on laboratory findings. J Lab Clin Med. 1979;93:1054-1065.
2. Eisenberg PR, Sherman LA, Schectman KA, Sobel BE, Jaffe AS. Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation. 1985;71:912-918.
3. Eisenberg PR, Sherman LA, Perez J, Jaffe AS. Relationship between elevated plasma levels of crossed linked fibrin degradation products (XL-FDP) and the clinical presentation of patients with myocardial infarction. Thromb Res. 1987;46:109-120.
4. Francis CW, Connaghan DG, Scott W, Marder VJ. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation. 1987;75:1170-1177.
5. Nossel HI. Radioimmunoassay of fibrinopeptides in relation to intravascular coagulation and thrombosis. N Engl J Med. 1974;295: 428-432.
6. Eisenberg PR, Jaffe AS, Stump DC, Collen D, Bovill EG. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis. Circulation. 1990;82: 1159-1168.
7. Francis CW, Connaghan DG, Marder VJ. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction. Circulation. 1986;74:1027-1036.
8. Bounameaux H, Cirafici P, Moerloose PD, Slosman D, Reber G, Unger PF. Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism. Lancet. 1991;337:196-200.
9. Goldhaber SZ, Vaughan DE, Tumeh SS, Loscalzo J. Utility of cross-linked fibrin degradation products in the diagnosis of pulmonary embolism. Am Heart J. 1989;116:505-508.
10. Rowbotham BJ, Egerton-Vernon J, Whitaker AN, Elms MJ, Bunce IH. Plasma cross linked fibrin degradation products in pulmonary embolism. Thorax. 1990;45:684-687.
11. Lichey J, Reschofski I, Dissmann T, Priesnitz M, Hoffmann M, Lode H. Fibrin degradation product D-dimer in the diagnosis of pulmonary embolism. Klin Wochenschr. 1991;69:522-526.
12. Demers C, Ginsberg JS, Johnston M, Brill-Edwards P, Panju A. D-dimer and thrombin-antithrombin III complexes in patients with clinically suspected pulmonary embolism. Thromb Haemost. 1992; 67:408-412.
13. Carter CJ, Doyle DL, Dawson N, Fowler S, Devine DV. Investigations into the clinical utility of latex D-dimer in the diagnosis of deep venous thrombosis. Thromb Haemost. 1993;69:8-11.
14. Rowbotham BJ, Carroll P, Whitaker AN, Bunce IH, Cobcroft RG, Elms MJ, Masci PP, Bundesen PG, Rylatt DB, Webber AJ. Measurement of cross-linked fibrin derivatives: use in the diagnosis of venous thrombosis. Thromb Haemost. 1987;57:59-61.
15. Ott P, Astrup L, Hartving JR, Nyeland B, Pedersen B. Assessment of D-dimer in plasma: diagnostic value in suspected deep venous thrombosis of the leg. Acta Med Scand. 1988;224:263-267.
16. Lee AJ, Fowkes FGR, Lowe GDO, Rumley A. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost. 1995;3:828-832.